GMT EIGHT - Market

HK Stock Market Move | XINYI ENERGY (03868) surged over 9%, core financial report slightly exceeded expectations last year, company's profit uncertainty is expected to decrease.

XINYI ENERGY (03868) surged more than 9%, rising by 9.28% to 1.06 Hong Kong dollars as of the time of writing, with a trading volume of 29.1 million Hong Kong dollars. In terms of news, XINYI ENERGY recently announced its annual performance, with a revenue of 2.44 billion yuan in 2024, an increase of 7% year-on-year; a net profit of 791 million yuan, a decrease of 12% year-on-year; basic earnings per share of 9.55 cents; proposing a final dividend of 2.7 Hong Kong cents per share, compared to 2.6 Hong Kong cents in the same period last year. Along with an interim dividend of 2.3 Hong Kong cents per share, a total of 5 Hong Kong cents will be distributed for the year. BOCOM INTL stated that due to the improved profit certainty of the company and the overall market valuation, the valuation benchmark has been increased from 8.5 times the 2025 P/E ratio to 9.5 times, with the target price raised from 1.02 Hong Kong dollars to 1.17 Hong Kong dollars. The company's dividend yield for 2025 is currently as high as 7.7%, and it is considered attractive in terms of valuation, maintaining a "buy" rating. BOCOM INTL believes that XINYI ENERGY achieved revenue and net profit of 2.44 billion and 791 million yuan respectively last year, with a year-on-year increase of 7% and a decrease of 12%. Excluding a 38 million yuan impairment of goodwill, the core financial reports exceeded the bank's expectations by about 4%, mainly due to factors such as a decrease in abandonment rate in the second half of the year pushing electricity sales volume beyond expectations. The report indicates that the new policies on renewable energy generation and tariff reform by the government are expected to ensure the stability of the company's existing project electricity prices after a rapid decline, reducing profit uncertainty.

5 min ago

HK Stock Market Move | UBOX ONLINE (02429) falls more than 8% in early trading, plans to discount approximately 14.97% of H shares for issuance, and net raise approximately HK$1.49 billion.

UBOX ONLINE(02429) fell more than 8% in the morning session, dropping by 7.91% as of the time of writing to 3.26 Hong Kong dollars, with a trading volume of 23.1253 million Hong Kong dollars. In terms of news, UBOX ONLINE announced plans to issue 51.6355 million new H shares at a price of 3.01 Hong Kong dollars per share, a discount of 14.97% compared to the closing price of 3.54 Hong Kong dollars on March 6; the net proceeds from the issuance are expected to be 1.492 billion Hong Kong dollars, with approximately 60% to be used to purchase fixed assets, including vending machines, and approximately 40% for operating capital and other general corporate purposes. UBOX ONLINE is reportedly the largest unmanned retail business operator in China. The company debuted on the Hong Kong Stock Exchange on November 3, 2023. On November 4, 2024, UBOX ONLINE marked its one-year anniversary of listing and entered the unlock period, during which the largest shareholders and chairman Wang Bin, former president Chen Kunrong, as well as cornerstone investors NAYUKI and Malacca, will have their restricted shares unlocked, with over 200 million shares involved, accounting for 27.88% of UBOX ONLINE's total share capital.

11 min ago

Hong Kong stock concept tracking| Copper prices are expected to rise under the consensus of mineral shortage (with concept stocks attached)

The price of copper in the New York market surged over 5% on Wednesday, further surpassing other global benchmark prices, after U.S. President Donald Trump hinted at imposing a 25% tariff on copper imports. Trump mentioned imposing tariffs on copper during his address to Congress on Tuesday, causing traders to worry that the tariffs may be higher and implemented sooner than expected, leading to a frenzy of price increases on the New York Mercantile Exchange during the Asian session. According to ANZ Bank, the U.S. may find it difficult to replace imported aluminum and copper, as the country heavily relies on overseas supplies. "U.S. has limited ability in the short term to substitute imported refined copper with domestic supply," ANZ Bank stated in a report, adding that in the medium term, the U.S. has relatively low interest in investing in new primary smelting capacity. Huayuan Securities released a research report stating that under the consensus of supply shortage, the price center is expected to rise. Based on the impact of global copper mining capital expenditure, capacity expansion, and disruptive events such as strikes on the operating rate, the current period may still be in a period of production expansion, but with a declining growth rate. As the shortage at the mine gradually transmits to the metal end and the growth rate of secondary copper smelting declines, the copper industry as a whole remains in a tight balance, with supply and demand expected to be balanced at 170,000, 70,000, 160,000, and 260,000 tons in 2024-2027. Copper mining company-related Hong Kong stocks include: CMOC Group Limited (03993): According to CMOC Group Limited, following the "strong start" in January 2025, its TFM company achieved a historical record in cathode copper production in February, exceeding the planned targets in terms of ore processing volume. Zijin Mining Group (02899): Zijin Mining Group plans to continue increasing its production in 2025: producing 1.15 million tons of copper, 85 tons of gold, 440,000 tons of zinc (lead), equivalent to 40,000 tons of lithium carbonate, 450 tons of silver, and 10,000 tons of molybdenum. MMG (01208): The company is a medium to large-sized non-ferrous metal mining company, mainly engaged in the exploration and development of overseas copper, zinc and other metal mines, serving as a platform for overseas resources integration of the Minmetals Group, with a copper equity production of 265,000 tons in 2024, ranking third among domestic listed companies, behind Zijin Mining Group and CMOC Group Limited. Copper is the core product of the company, accounting for 76% of the company's operating income in 2023, with zinc accounting for 8.3%. The core mine Las Bambas copper mine has resumed normal operations, with production increasing and costs sharply reduced. Las Bambas copper mine is one of the top 10 copper mines in the world, with a copper resource of 8.7 million tons, reserves of 4.6 million tons, producing 323,000 tons of copper in 2024, expected to produce 400,000 tons of copper in 2025. In 2023, the revenue from the Bambas copper mine accounted for 79% of the company, EBITDA accounted for 92% of the company, and as of mid-2024, the Bambas copper mine assets accounted for 62% of the company, being the core mine of the company.

12 min ago

HK Stock Market Move | YONGHE MEDICAL (02279) rose more than 9% in early trading, store optimization and marketing upgrades helped the company significantly narrow its full-year losses.

YONGHE MEDICAL (02279) rose more than 9% in the morning session, as of press time, it was up 7.27% at HKD 1.18. On the news front, YONGHE MEDICAL released a performance forecast, expecting the net loss to shrink by no less than about 55% compared to last year. This is mainly attributed to the optimization of the store network layout last year, the closure and integration of inefficient stores, and the concentration of resources on core stores, significantly improving operational efficiency; the self-developed chain medical management system "Hefan" has been fully implemented, achieving refined management in multiple processes. These measures have increased gross profit and gross profit margin by approximately 7% to 10% and 3 to 5 percentage points respectively compared to the same period in 2023. In addition, the group has implemented a refined marketing strategy, dynamically adjusting marketing channels through big data analysis, effectively improving customer acquisition efficiency and return on investment; at the same time, streamlining the organizational structure to enhance team efficiency. These measures have effectively controlled costs while improving efficiency, resulting in a decrease in sales and marketing expenses and general and administrative expenses by about 8.0% to 9.0% and 5.0% to 6.0% respectively compared to the same period in 2023.

18 min ago

HK Stock Market Move | MARKETINGFORCE(02556) rose nearly 7% during the day. AI Agent welcomes a new catalyst as the company builds an intelligent body middle platform to empower SaaS products.

MARKETINGFORCE (02556) rose nearly 7% in midday trading, and at the time of publication, it had risen 5.77% to 68.7 Hong Kong dollars, with a trading volume of 2.81 billion Hong Kong dollars. On the news front, on March 6, Monica.im released the world's first universal AI Agent product, Manus AI, which surpasses OpenAI DeepResearch. It is reported that MARKETINGFORCE previously announced that the AI Agent product is fully integrated into DeepSeek-V3 and DeepSeek-R1, integrating them into the AI-Agentforce middle platform to create a more innovative and competitive intelligent marketing sales full-chain solution for enterprise customers. Zheshang pointed out that the company is a leading domestic marketing and sales SaaS provider, and has built a complete product matrix for small and KA customers. At the same time, it is actively deploying AI big model functions combined with enterprise management applications, and is expected to build an AI Agent product matrix on the basis of SaaS services in the future. The bank believes that the company is expected to benefit from the growth of downstream enterprise customers' digitization needs and the accelerating penetration of AI applications, achieving rapid overall business growth.

18 min ago

HK Stock Market Move | BIOCYTOGEN-B(02315) contrary to the trend, rose more than 10%. The localization deployment of the AI-driven antibody drug research platform DeepSeek has been completed.

BIOCYTOGEN-B (02315) rose by over 10% against the market trend, rising by 10.07% to HK$12.02 as of the time of writing, with a turnover of HK$125,200. On the news front, BIOCYTOGEN-B announced that the company has recently completed the localization deployment of the artificial intelligence (AI)-driven antibody drug research platform DeepSeek, and has achieved comprehensive coordination with the company's core business "Thousand Mice, Ten Thousand Antibodies" plan. This technical integration signifies a new stage of intelligence and data-driven antibody drug early-stage research, which will provide more precise and breakthrough antibody drug research solutions for global pharmaceutical companies in the future, greatly accelerating the drug development process. According to reports, By-Health, through the combination of the "Thousand Mice, Ten Thousand Antibodies" antibody molecular library and the DeepSeek platform, can provide global pharmaceutical companies with new single, double, and multiple antibody molecular frameworks. These molecular frameworks have high affinity, low immunogenicity, and excellent drug-like properties. With the DeepSeek platform, global pharmaceutical companies can quickly screen out target antibody molecules with extremely high drug potential from the existing million-level antibody molecular library of "Thousand Mice, Ten Thousand Antibodies". DeepSeek can also use simulated molecular interactions to screen and obtain molecular frameworks from the huge antibody molecular library of "Thousand Mice, Ten Thousand Antibodies" and rapidly design multi-specific antibodies with specific functions, such as double antibodies and multiple antibodies, to rapidly develop innovative antibody drugs for various diseases, greatly accelerating the drug development process and meeting unmet clinical needs.

18 min ago

HK Stock Market Move | Ganfeng Lithium Group (01772) and Tianqi Lithium Corporation (09696) both rose more than 4% against the market trend.

Lithium stocks rise against the market. As of the time of writing, Tianqi Lithium Corporation (09696) rose by 3.14% to 26.25 Hong Kong dollars, and Ganfeng Lithium Group (01772) rose by 2.76% to 24.2 Hong Kong dollars. In terms of news, GGII released a report stating that it is expected that the compound growth rate of data center energy storage lithium batteries will exceed 80% in the next five years. In addition, the lithium battery industry is experiencing a wave of capacity expansion, with several companies in the lithium battery industry chain announcing capacity expansions since February. Industry insiders have stated that since the beginning of this year, the domestic lithium battery production has shown signs of warming up. Xiangcai Securities also pointed out that the bidding for energy storage procurement is still hot in 2025, and the demand for energy storage is still in good shape. Mineral Securities stated that after the holiday, lithium salt factories have successively resumed production, and the supply from leading companies has recovered, with overall production growth rate being relatively fast. At the same time, due to the fact that most overseas mainstream lithium mines adopt long-term supply agreements, the majority of lithium ore in the market comes from regions like Zimbabwe and Nigeria. Additionally, recent shipping disruptions in Africa have caused lithium ore prices to be relatively lower than salt factories. Currently, due to high hedging positions at the end of 2024, lithium salt factories still have acceptable levels of ore price acceptance. If there are no unexpected increases in demand in the future, it will be difficult for ore prices to continue to remain high.

24 min ago

HK Stock Market Move | Zhengzhou Coal Mining Machinery Group (00564) rose more than 3% during trading hours. Its subsidiary company has integrated DeepSeek to inject AI capabilities into the core system of smart mines.

Zhengzhou Coal Mining Machinery Group (00564) rose more than 3% during trading, and at the time of writing, it had risen by 2.46% to 11.68 Hong Kong dollars, with a trading volume of 1137.68 million Hong Kong dollars. On the news front, on March 4th, the official WeChat account mentioned that recently, the full-stack domestic AI platform built by Zhengzhou Coal Mining Machinery Group's Hengda Intelligent Control Company based on the DeepSeek large model and Huawei Ascend AI server was successfully completed. This milestone achievement signifies that the "independently controllable large model + domestic computing power hardware" solution has officially taken root in the field of intelligent coal mining, heralding the full localization of the era of intelligent coal mining. Successful deep integration in the intelligent mining field includes DeepSeek with mine pressure monitoring system, overall mine shaft control platform, comprehensive mining control platform, AI video analysis, digital twin system, industrial Internet, and comprehensive disaster prevention and control systems. A spokesperson for Zhengzhou Coal Mining Machinery Group said, "By achieving full-stack independent controllability and integrating coal mine production, safety, warning, and analysis businesses into the DeepSeek industry large model, and deeply integrating with Huawei Ascend AI computing power. From underlying algorithms to upper-level frameworks, and to hardware facilities, full localization adaptation has been achieved in all aspects. This not only strengthens the solid defense line for coal mine data security but also achieves a qualitative leap in response speed. Deep integration of DeepSeek large model technology injects AI capabilities into the core system of intelligent mining, enhancing production efficiency and safety control."

24 min ago

Hong Kong stock concept tracking | Deepseek triggers AI medical boom, boosting pharmaceutical sector valuation (attached concept stocks)

In 2024, the total number of outpatient visits in medical and health institutions nationwide was 10.11 billion, an increase of 5.8% year-on-year. In 2024, the total income of the national basic medical insurance fund was 3.48 trillion yuan, an increase of 4.4% year-on-year, with total expenditure of 2.97 trillion yuan, an increase of 5.5% year-on-year, indicating a slight slowdown in the rapid growth of expenditure. Frost & Sullivan predicts that by 2033, the market size of the AI medical industry in China will increase from 8.8 billion yuan in 2023 to 315.7 billion yuan, with a compound annual growth rate of 43.1%. DeepSeek has triggered a wave of AI medical applications, boosting the valuation of the pharmaceutical sector. Since the beginning of 2025, DeepSeek has sparked a wave of AI medical applications, with companies in the industry quickly deploying localized applications of DeepSeek, significantly improving the performance of professional large models. AI will widen the gap between industry leaders and followers, helping to increase market share in core businesses, and derive new services and functionalities from AI applications, bringing incremental growth to the industry in the long term. China Galaxy Securities released a research report stating that in terms of AI medical applications, new drug research and development, intelligent equipment, diagnostic services, and physical examination services are expected to advance rapidly, potentially enhancing the valuation of the pharmaceutical sector. Tianfeng Research report stated that with the opening of the AI era, the core contradiction in AI medical technology is shifting from a "big model + computing power arms race" to a "revaluation of data value." The medical industry, as a highly specialized industry with high barriers, will have the opportunity to achieve leapfrog growth by having high-quality data, rare application scenarios, and mastering the race track and enterprises with multimodal fusion data. It is recommended to focus on directions related to high-quality data, rare application scenarios, and multimodal fusion data, such as AI + health management, AI + detection diagnosis and treatment, AI + doctor digital platform, AI + medical informationization, and AI + drug development. AI medical-related Hong Kong stocks include: Crystal Optech (2228), ALI HEALTH (0241), JD HEALTH (6618), Ping An Health (1833), YIDU TECH (2158), Microc Siasun Robot&Automation (2252), Gu Sheng Tang (2273), MEDLIVE (2192), etc. iFLYTEK Medical (02506): As the only medical deep reasoning large model trained with national-produced computing power, the X1 Starfire Medical Large Model's performance in medical tasks such as diagnostic recommendations and health consultations surpasses that of GPT-4o and DeepSeek R1, marking a major technological breakthrough in the field of AI medical technology. Iflytek Co.,ltd. has launched the iFLYTEK Starfire Medical All-in-One Machine in partnership with Huawei, which is based on the technical ability of the X1 Starfire Medical Large Model, supporting full-stack localization, rapid deployment, out-of-the-box use, data non-exit domain, and data security. HEC CJ PHARM (01558): Since 2023, Guangdong Hec Technology Holding has cooperated with Huawei Cloud in AI drug research and development, optimizing the high-precision molecular properties and drug structures. From drug discovery to pharmaceutical processes, a one-stop out-of-the-box large model drug research platform has been created. On December 16th last year, Guangdong Hec Technology Holding's AI-driven Class 1 new drug, the first small molecule innovative drug HEC169584, was approved for clinical trials for non-alcoholic fatty liver disease (NASH). HEC169584 is the first candidate drug obtained by Guangdong Hec Technology Holding through AI-driven small molecule drug design platform. YIDU TECH (02158): YIDU TECH is committed to promoting cutting-edge innovation in AI medical technology, using the "AI Medical Brain" YiduCore to create professional, efficient, precise, and inclusive artificial intelligence products and solutions in public health, clinical and disease research, medical management, new drug research and health management fields. Recently, YIDU TECH announced the integration of the DeepSeek artificial intelligence model into its self-developed "AI Medical Brain" YiduCore, which will further promote the large-scale application and innovative practice of AI technology in the medical and health industry. Ping An Health (01833): Building on its "Ping An Medical Note" multimodal large model and "Ping An Family Doctor" doctor workstation, Ping An Health has recently completed the deployment of DeepSeek and some scenario applications. Access to DeepSeek signifies a transition from pure digital services to comprehensive intelligence. By integrating DeepSeek's strong computing power and algorithm advantages, the deep application of AI technology in medical services, Ping An Health's user base and revenue levels are expected to further improve, driving the growth of the company's valuation. JD HEALTH (06618): In January of this year, the company released the industry's first hospital full-scenario application large model product "JD Zhuoyi", announcing the official launch of the first batch of digital doctors on the Internet doctor platform. In February, it was announced that the company's self-owned medical large model "Jingyi Qianxun" has been integrated with general models such as GPT series, DeepSeek, and has been open sourced, meaning that all model parameters, data construction, multi-stage model training, model evaluation and other core code will be public.

29 min ago

HK Stock Market Move | MIXUE GROUP (02097) rose by over 10% to reach a new high, with its stock price increasing by over 80% in just five days of being listed. Its total market value has exceeded HK$140 billion.

MIXUE GROUP (02097) rose more than 10% to a high of 378 Hong Kong dollars, reaching a new high for the listing, an increase of more than 80% compared to the IPO price of 202.5 Hong Kong dollars. As of the time of writing, it had risen by 10.43%, to 377 Hong Kong dollars, with a trading volume of 1.15 billion Hong Kong dollars, and a total market value exceeding 140 billion Hong Kong dollars. Pacific Securities pointed out that the company achieves ultimate cost control through vertical integration of the supply chain, penetrates the sinking market with a low-price strategy, and then feeds back the supply chain efficiency with a super large-scale, forming a closed loop. Its moat lies in the continuously iterative supply chain capabilities and economies of scale. In addition, overseas expansion and Lucky Tea build the second growth curve. The current Southeast Asian ready-to-drink beverage market is in a period of rapid development, with a CAGR of 19.8% expected for 2023-2028, leading other regions globally. MIXUE is the largest tea beverage brand in terms of store scale in Southeast Asia, with 4792 overseas stores as of September 2024. The company is also expanding in developed countries such as Japan, Korea, and Australia, with vast overseas opportunities. China Securities Co., Ltd. believes that the future of the domestic ready-to-drink tea industry is expected to further enhance the average consumption per capita and stickiness. There is still ample room for growth in the race, mainly based on trends of healthyization and supply chain control of top materials, product category iteration and upgrade, scale and accessibility improvement, overseas expansion advantages in category, and refinement in management reshaping the logic of people, goods, and fields. Leveraging its leading scale advantage and deep industry chain cultivation advantage in China, the company has relatively high comprehensive competitive barriers, thick global momentum-building, and is poised to continue promoting industry development and global deployment.

33 min ago

Contact: contact@gmteight.com